FDA warns Novo Nordisk over unreported potential Ozempic side effects
Novo Nordisk, the pharmaceutical company behind Ozempic, has received a warning letter from the U.S. Food and Drug Administration over issues with its procedures for reporting potential side effects of the flagship diabetes drug, which is also prescribed for weight loss. In the letter, dated March 5, the FDA cited three deaths among patients receiving … Read more